Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer

BACKGROUND: Anti-PD-1(L1) therapies are less efficacious in patients with EGFR-mutated non-small-cell lung cancer. However, the underlying mechanism is poorly understood. METHODS: The characteristics of T cells in EGFR-mutated and wild-type tumors were analyzed based on The Cancer Genome Atlas datab...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiao, Meng, Zhou, Fei, Liu, Xinyu, Jiang, Tao, Wang, Haowei, Jia, Yijun, Li, Xuefei, Zhao, Chao, Cheng, Lei, Chen, Xiaoxia, Ren, Shengxiang, Liu, Hongcheng, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772697/
https://www.ncbi.nlm.nih.gov/pubmed/36543373
http://dx.doi.org/10.1136/jitc-2022-005436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772697/
https://www.ncbi.nlm.nih.gov/pubmed/36543373
http://dx.doi.org/10.1136/jitc-2022-005436

Ejemplares similares